Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer

  • Hans Christiansen
  • Bernhard Saile
  • Robert M. Hermann
  • Margret Rave-Fränk
  • Andrea Hille
  • Heinz Schmidberger
  • Clemens F. Hess
  • Giuliano Ramadori
Original Paper

Abstract

Purpose

To analyse hepcidin serum and urine levels during radiotherapy for prostate cancer.

Methods

In 18 patients undergoing radiotherapy for prostate cancer, blood, plasma, and urine samples were taken before and during radiotherapy. Complete blood cell count, pro-hepcidin-, ferritin-, transferrin-, IL-1β-, IL-6-, and TNF-α concentration was determined. Pro-hepcidin concentration was additionally measured in urine samples. Toxicity was evaluated weekly. Differences among tested factors were tested by Wilcoxon rank sign test for paired data.

Results

In ten patients developing acute radiation-induced proctitis, a significant increase in pro-hepcidin, IL-6, and TNF-α plasma levels (p < 0.05) was detected. Pro-hepcidin urine levels also showed a strong trend towards increase (p = 0.06). Concurrently, hemoglobin, and leucocytes were significantly decreased in the patients with acute proctitis (p < 0.05). In eight patients showing no symptoms of proctitis, solely a significant decrease for leucocytes was detected. Additive, these patients showed a significant increase of ferritin, and a decrease of transferrin levels (p < 0.05).

Conclusions

Hepcidin levels are increased and hemoglobin is decreased during radiotherapy for prostate cancer in patients who develop acute proctitis. Radiation-induced expression of cytokines may be responsible for increased hepcidin expression in the liver. Regulation of iron metabolism by hepcidin may be an underestimated response in radiotherapy.

Keywords

Hepcidin Radiotherapy Prostate cancer Proctitis Cytokines 

References

  1. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995PubMedCrossRefGoogle Scholar
  2. Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF, Carrie C (2005) Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23:8748–8756PubMedCrossRefGoogle Scholar
  3. Boustany R, Zerbib M (2005) Anaemia and prostatic cancer. Prog Urol 15:604–610PubMedGoogle Scholar
  4. Christiansen H, Sheikh N, Saile B, Reuter F, Rave-Frank M, Hermann RM, Dudas J, Hille A, Hess CF, Ramadori G (2006) X-radiation leads to up-regulation of hepcidin and down-regulation of hemojuvelin and ferroportin-1 gene expression in rat liver. Radiology (in press)Google Scholar
  5. Corradini E, Ferrara F, Pietrangelo A (2004) Iron and the liver. Pediatr Endocrinol Rev 2:245–248PubMedGoogle Scholar
  6. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783–788PubMedCrossRefGoogle Scholar
  7. Ganz T (2004) Hepcidin in iron metabolism. Curr Opin Hematol 11:251–254PubMedCrossRefGoogle Scholar
  8. Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290:G199–G203PubMedCrossRefGoogle Scholar
  9. Harrison LB, Shasha D, Homel P (2002) Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 63:11–18PubMedCrossRefGoogle Scholar
  10. Herskind C, Bamberg M, Rodemann HP (1998) The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174:12–15PubMedGoogle Scholar
  11. Indaram AV, Visvalingam V, Locke M, Bank S (2000) Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol 95:1221–1225PubMedCrossRefGoogle Scholar
  12. International Commission on Radiation Units and Measurements (1993) Prescribing, recording and reporting photon beam therapy. ICRU Report No. 50, MP, BethesdaGoogle Scholar
  13. Jurado RL (1997) Iron, infections, and anemia of inflammation. Clin Infect Dis 25:888–895PubMedGoogle Scholar
  14. Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26:1494–1497PubMedCrossRefGoogle Scholar
  15. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, Jansen PP, Hanssens PE, Griep C, Krol AD, Samson MJ, Levendag PC (1997) Acute morbidity reduction using 3DCRT for prostate carcinoma (a randomized study). Int J Radiat Oncol Biol Phys 43:727–734CrossRefGoogle Scholar
  16. Kovacs CJ, Daly BM, Evans MJ, Johnke RM, Lee TK, Karlsson UL, Allison R, Eaves GS, Biggs LM (2003) Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23:151–163PubMedCrossRefGoogle Scholar
  17. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480:147–150PubMedCrossRefGoogle Scholar
  18. Lee P, Peng H, Gelbart T, Wang L, Beutler E (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 102:1906–1910PubMedCrossRefGoogle Scholar
  19. Lipinski P, Starzynski R (2004) Regulation of body iron homeostasis by hepcidin. Postepy Hig Med Dosw 58:65–73Google Scholar
  20. Lipman AJ, Lawrence DP (2004) The management of fatigue in cancer patients. Oncology (Williston Park) 18:1527–1535Google Scholar
  21. McGrath H, Rigby PG (2000) Hepcidin: inflammation’s iron curtain. Rheumatology 43:1323–1325CrossRefGoogle Scholar
  22. Means RT (1999) Advances in the anemia of chronic disease. Int J Hematol 70:7–12PubMedGoogle Scholar
  23. Means RT (2004) Hepcidin and cytokines in anaemia. Hematology 9:357–362PubMedCrossRefGoogle Scholar
  24. Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD (2000) Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391–402PubMedCrossRefGoogle Scholar
  25. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461–2463PubMedCrossRefGoogle Scholar
  26. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271–1276PubMedCrossRefGoogle Scholar
  27. Ozsahin M, Azria D, Beer K, Mirimanoff RO, Zouhair A (2005) External radiotherapy and anaemia treatment: state of the art. Swiss Med Weekly 135:4–10Google Scholar
  28. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810PubMedCrossRefGoogle Scholar
  29. Petrini B, Andersson B, Strannegard O, Wasserman J, Blomgren H, Glas U (1992) Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. In Vivo 6:531–534PubMedGoogle Scholar
  30. Pietrangelo A (2005) Non-HFE hemochromatosis. Semin Liver Dis 25:450–460PubMedCrossRefGoogle Scholar
  31. Rube CE, Rodemann HP, Rube C (2004) The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance. Strahlenther Onkol 180:541–549PubMedGoogle Scholar
  32. Sharma N, Butterworth J, Cooper BT, Tselepis C, Iqbal TH (2005) The emerging role of the liver in iron metabolism. Am J Gastroenterol 100:201–206PubMedCrossRefGoogle Scholar
  33. Sheikh N, Batusic D, Dudas J, Tron K, Neubauer K, Saile B, Ramadori G (2006) Hepcidin and hemojuvelin gene-expression in rat liver damage: in vivo and in vitro studies. Am J Physiol Gastrointest Liver Physiol 291:G482–490PubMedCrossRefGoogle Scholar
  34. Sobin LH, Wittekind C (1997) TNM classification of malignant tumours, 5th edn. Wiley/Liss, New YorkGoogle Scholar
  35. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I (2000) Complications from radiotherapy dose escalation in prostate cancer (preliminary results of a randomized trial). Int J Radiat Oncol Biol Phys 48:635–642PubMedCrossRefGoogle Scholar
  36. Theodorsson E (2006) Haemochromatosis, hepcidin and disorders of iron metabolism: fields of substantial clinical relevance and current advances. Scand J Clin Lab Invest 66:79–82PubMedCrossRefGoogle Scholar
  37. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47PubMedCrossRefGoogle Scholar
  38. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hans Christiansen
    • 1
  • Bernhard Saile
    • 2
  • Robert M. Hermann
    • 1
  • Margret Rave-Fränk
    • 1
  • Andrea Hille
    • 1
  • Heinz Schmidberger
    • 1
    • 3
  • Clemens F. Hess
    • 1
  • Giuliano Ramadori
    • 2
  1. 1.Department of Radiation OncologyUniversity Hospital GoettingenGoettingenGermany
  2. 2.Department of Gastroenterology and EndocrinologyUniversity Hospital GoettingenGoettingenGermany
  3. 3.Department of RadiotherapyMainz UniversityMainzGermany

Personalised recommendations